Acute myeloid leukemia (AML) is a polyclonal and heterogeneous hematological
malignancy. Relapse and refractory after induction chemotherapy are still challenges for …

TET2 is recurrently mutated in acute myeloid leukemia (AML) and its deficiency promotes
leukemogenesis (driven by aggressive oncogenic mutations) and enhances leukemia stem …

The central role of the endothelial microenvironment in orchestrating bone marrow (BM)
homeostasis and hematopoietic support has been confirmed at various developmental …

As the most common internal modification of mRNA, N 6-methyladenosine (m 6 A) and its
regulators modulate gene expression and play critical roles in various biological and …

The mechanisms underlying the transformation of chronic myeloid leukemia (CML) from
chronic phase (CP) to blast crisis (BC) are not fully elucidated. Here, we show lower levels of …

Leukemia is a malignancy in the blood that develops from the lymphatic system and bone
marrow. Although various treatment options have been used for different types of leukemia …

MiR-126 and miR-155 are key microRNAs (miRNAs) that regulate, respectively,
hematopoietic cell quiescence and proliferation. Herein we showed that in acute myeloid …

Acute myeloid leukaemia (AML) is a malignant disease of myeloid hematopoietic
stem/progenitor cells. Despite improved understanding of the pathogenesis of AML since the …

Although chemotherapeutic regimens can eliminate blasts in leukaemia patients, such
therapies are associated with toxicity and often fail to eliminate all malignant cells resulting …

Acute myeloid leukemia (AML) is the most common type of hematological malignancy.
Recently, an increasing number of reports have shown that many circular RNAs can act as …